News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Qurat Ul Ain Sabih

Articles by Qurat Ul Ain Sabih

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

ByMutlu Dogan,Berk Goktepe,Mehmet Bilici,Sercan Aksoy,Fatih Selcukbiricik,Ali Alkan,Arzu Oguz,Arzu Yasar,Naziye Ak,Betul Ersoz,Lutfi Dogan,Merve Tokocin,Yasemin Evlendi,Ozlem Soran,Qurat Ul Ain Sabih,Julia Foldi,Atilla Soran, MD, MPH

June 6th 2026

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

ByLeslie Elmore,Neil Carleton,Michael S. Cowher,Rohit Bhargava,Emilia Diego,Kristin Lupinacci,Meaghan Marley,Qurat Ul Ain Sabih,Atilla Soran, MD, MPH,Jennifer Steiman,Ronald Johnson,Erin Bayley,Priscilla F. Mcauliffe, MD, PhD

May 17th 2025

Latest Updated Articles

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology